It can take up to six years to accumulate enough evidence to support advancing an experimental drug into clinical development. twoXAR is working to rapidly accelerate that process through the use of Big Data and its proprietary algorithms to find screen large public and proprietary data sets to indentify new drug candidates and determine their efficacy. We spoke to Andrew Radin, co-founder and CEO of twoXAR, about the company’s technology, how it’s being applied today, and the evolution of the company’s strategy.

The mindset of “move fast and break things”, while great for code, isn’t exactly great for the human body. So adding computation to biology — especially in the slow-moving pharmaceutical industry, where drug approval can take years — brings with it both opportunities (like drastically faster discovery and assessment) and challenges (the need for hard evidence, not just soft-ware). But there’s more: We don’t want just better outcomes for healthcare. We want better outcomes at a cheaper price.